Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 6/20 | 0.67 |
| ▸ | CDK1 | P06493 | 6/20 | 0.67 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.67 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.67 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.61 |
| ▸ | CDK2 | P24941 | 4/20 | 0.61 |
| ▸ | NFATC1 | O95644 | 2/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | IGF1R | P08069 | 3/20 | 0.61 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | PRKCA | P17252 | 2/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13051126 | 0.91 | DYRK1B (0.60) | CCNB2CDK1CCNB1CCNB3DYRK1B | |
| SCHEMBL1586801 | 0.90 | CCNB2 (0.67) | CCNB2CDK1CCNB1CCNB3DYRK1B | |
| SCHEMBL31588329 | 0.88 | CCNB2 (0.76) | CCNB2CDK1CCNB1CCNB3DYRK1A | |
| SCHEMBL144954 | 0.88 | CCNB2 (0.76) | CCNB2CDK1CCNB1CCNB3DYRK1A | |
| SCHEMBL13051119 | 0.86 | ABL1 (0.55) | CCNB2CDK1CCNB1CCNB3DYRK1B | |
| SCHEMBL13051120 | 0.86 | ABL1 (0.58) | CCNB2CDK1CCNB1CCNB3DYRK1B | |
| SCHEMBL13051125 | 0.85 | DYRK1B (0.61) | CCNB2CDK1CCNB1CCNB3DYRK1B | |
| SCHEMBL30847342 | 0.84 | ABL1 (0.57) | CCNB2CDK1CCNB1CCNB3DYRK1B | |
| SCHEMBL13051121 | 0.84 | CDK2 (0.56) | CCNB2CDK1CCNB1CCNB3DYRK1B | |
| SCHEMBL27109944 | 0.84 | ABL1 (0.57) | CCNB2CDK1CCNB1CCNB3DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292262-A1 | 4 (PYRROLO[2,3-C]PYRIDINE-3-YL)PYRIMIDIN-2-AMINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-18 | — | — | US | claimed |
| CN-101723936-B | Kinase suppressor and pharmaceutical application thereof | SHANGHAI GENOMICS INC | 2014-01-15 | — | — | CN | disclosed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
| US-20100292262-A1 | 4 (PYRROLO[2,3-C]PYRIDINE-3-YL)PYRIMIDIN-2-AMINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292262-A1 | 4 (PYRROLO[2,3-C]PYRIDINE-3-YL)PYRIMIDIN-2-AMINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-18 | — | — | US | disclosed |
| EP-2231664-A1 | 4-(PYRROLOÝ2,3-C¨PYRIDINE-3-YL)-PYRIMIDINE-2-AMINE DERIVATIVES | Merck Patent GmbH (DE) | 2010-09-29 | — | — | EP | disclosed |
| CN-101723936-A | Kinase suppressor and pharmaceutical application thereof | SHANGHAI GENOMICS INC | 2010-06-09 | — | — | CN | disclosed |
| WO-2010051781-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC. (CN) | 2010-05-14 | — | — | WO | disclosed |
| WO-2009092431-A1 | 4-(PYRROLO[2,3-C]PYRIDINE-3-YL)-PYRIMIDINE-2-AMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009092431-A1 | 4-(PYRROLO[2,3-C]PYRIDINE-3-YL)-PYRIMIDINE-2-AMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | MAP3K20, MAP3K1, MAP3K2 | CCNB2 1037/4885CDK1 129/4885CCNB1 1308/4885 |
| US-20100292262-A1 | 4 (PYRROLO[2,3-C]PYRIDINE-3-YL)PYRIMIDIN-2-AMINE DERIVATIVES | MKI67, CDK4, CCNT1 | CCNB2 26/4885CDK1 9/4885CCNB1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.